Trials / NCT05147701
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
Recruiting now Phase 1 Cell therapy
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Treatment
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Gene
- Not stated
- Conditions
- Eye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration, Traumatic Optic Neuropathy, Optic Atrophy
- Ages
- Any to no upper limit
- Enrollment
- 20 participants
- Started
- 2022-02-01
- Main results expected
- 2028-01
- Results posted
- Not yet
- Record last updated
- 2026-10-16
What the study is testing
This trial will study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy
Where it runs
Greece (1)
- Prodromos Stem Cell Institute, Athens (recruiting now)
United States (1)
- Prodromos Stem Cell Institute, Naples, Florida (recruiting now)